The course of C-peptide levels in patients developing diabetes during anti-PD-1 therapy

The course of C-peptide levels in patients developing diabetes during anti-PD-1 therapy

Introduction: Immune checkpoint inhibitor (ICI) associated diabetes is a harmful adverse event (AE) in patients with cancer following anti-programmed (cell) death protein-1 (PD-1) treatment. There are no available biomarkers able to predict this AE. The primary aim of this study was to investigate C...

Full description

Bibliographic Details
Main Authors: Edwin A. Basak, Karlijn de Joode, Tom J.J. Uyl, Ronald van der Wal, Marco W.J. Schreurs, Sjoerd A.A. van den Berg, Esther Oomen-de Hoop, Cor H. van der Leest, Layal Chaker, Richard A. Feelders, Astrid A.M. van der Veldt, Arjen Joosse, Stijn L.W. Koolen, Joachim G.J.V. Aerts, Ron H.J. Mathijssen, Sander Bins
Format: Article
Language:English
Published: Elsevier 2022-12-01
Series:Biomedicine & Pharmacotherapy
Subjects:
Immunotherapy
Cancer treatment
C-peptide
Islet autoantibodies
Pancreatic enzymes
Online Access:http://www.sciencedirect.com/science/article/pii/S0753332222012288

Similar Items

Similar Items